Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What folks on this board have failed to recognize is that Tom V Wilen....the same man responsible for bringing Stolichnaya Vodka to the states....is the man heading up the HBRM vodka deal....read between the lines....this is a very big deal...
Since DERBY is restricted right now on HBRM iHUB...he's moving over to a much BIGGER site... The Lion.
Prepare for fireworks tomorrow.
Since DERBY is restricted right now on HBRM iHUB...he's moving over to a much BIGGER site... The Lion.
Prepare for fireworks tomorrow.
DERBY has the inside track on whats going on, too bad he's restricted on the board, but what he knows will FRY any shorts in HBRM in the VERY near future!
HBRM .0063 just printed...up 20%[/b
HBRM .0063 just printed...up 20%[/b
HBRM .0063 just printed...up 20%
HBRM .0059 just printed....onward and upward
HBRM .0059 just printed....onward and upward
HBRM is about to take a major move. Tom V. Wilen (solely responsbile for brining Stolichnaya Vodka to America now trading at 90 dollars is the man behind Kamasutra Vodka (HBRM and Bismark joint venture). Major distribution deal in the works...CHRI deal also alive and kicking!!!
HBRM is about to take a major move. Tom V. Wilen (solely responsbile for brining Stolichnaya Vodka to America now trading at 90 dollars is the man behind Kamasutra Vodka (HBRM and Bismark joint venture). Major distribution deal in the works...CHRI deal also alive and kicking!!!
I have a sneaking suspicion that we will be getting a very positive HBRM update about the CHRI deal soon.
Our Patron Saint of CEO couseling will be talking with the CEO over the weekend and consulting with her on S/S (getting it down smaller without a r/s) as well as PR "crafting" of the upcoming major news...
Sell at your own risk. Mon. could see MAJOR material event PR's
If people read the hbrm pr more carefully they would be buyers not sellers. This will be a great revenue stream. Approval by the alcohol board for the label and formula is no easy task in this country. In addition, TIM WILEN brought Stolichnya Vodka to this country. She is surrounded by big shots!!!!
NYC distributor already set up to market and sell HBRM Kamasutra. Tom Willen is connected!!!
How is Tom Willen connected to HBRM?
I just spoke with someone in marketing at: www.ourniche.com a nj liquor distributor who reps Bismark vodka...she was well aware of the PR and said a NYC distributor would be handling Kamasutra....this sounds to me like everything is lined up nicely for this HBRM deal!!! This is not fluff....
HBRM...I just spoke to the CEO....NEWS will be released after hours. Although she did not emphatically state that as it would be insider trader; I read through the lines. It sounds like it will be more than fantastic...
I don't think we see a buyout out today. That will come...this PR will foreshadow how big HBRM will be with there Chinese partners and describe innovative directions for radical revenue streams.
Will HBRM close at the HOD? I think so...
Will HBRM close at the high of the day? Lets take a poll!!! I say yes..
Will we close GREEN today? HOD?
I just spoke with CEO Agnes...of HBRM. She was courteous and thoughtful and said it was an honest mistake to put out the news on the holiday. While she maintained her professionality she alluded that a major partnership is at play....in a very innovative marketplace. I felt very confident after our call....she is bright and determined and ethical. This should rock....I will be a huge buyer going into Tuesday and beyond!!!
Do we gap up this morning or test .009? What are your thoughts? Let's go HBRM
Where do we close tomorrow? Any conservative guesses?
Do you think Chtp tanks further tomorrow or recovers?
Does this tank even further tomorrow or recover over 3 dollars?
Does this tank even further tomorrow or recover over 3 dollars?
NEOM...Green close prediction....???
The NEOM picture is becoming clearer. Dr. S is certainly at work putting together a collective of technologically advanced companies. NEOM will rocket very soon.
Have these individuals really worked for Dr S?
NEOM: Why is it trading sideways? Too many shares in the float? I took a large position last week but the trading is confusing? Dumping?
Let's get the word out to Mad Money and the big blogs to cover NEOM and the Drs investment. This is a huge story!!!
NEOM.. What is the current share structure? How many shares in the float?
Ill put my money where a Billionaire does any day...go NEOM
Do you really think a Billionaire really needs to be involved in a pump and dump scheme? Come on...be serious.
Tekmira Provides Update on Licensed Product Candidate, Marqibo(R)
Talon Therapeutics' Product Candidate Marqibo Receives a Positive Vote From the Oncologic Drugs Advisory Committee (ODAC)
Press Release: Tekmira Pharmaceuticals – 6 hours ago
2
Email
Print
Companies:
Talon Therapeutics, Inc.Tekmira Pharmaceuticals CorporationTekmira Pharmaceuticals Corp
RELATED QUOTES
Symbol Price Change
TLON.OB 0.81 0.00
VANCOUVER, British Columbia, March 22, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR - News) (TSX:TKM.TO - News), a leading developer of RNA interference (RNAi) therapeutics, disclosed that its licensing partner, Talon Therapeutics, Inc. (OTCBB:TLON.OB - News), announced today that the Oncologic Drugs Advisory Committee voted 7 yes, 4 no, and 2 abstain that evidence from clinical studies supports a favorable benefit/risk assessment for use of Marqibo(R) (vincristine sulfate liposomes injection) for the treatment of adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or that has progressed following two or more lines of anti-leukemia therapy. The FDA decision date for Marqibo is May 13, 2012.
Marqibo is a liposomal formulation of the chemotherapy drug vincristine. Marqibo, along with two other liposomal chemotherapy products, Alocrest (liposomal formulation of the chemotherapy drug vinorelbine) and Brakiva (liposomal formulation of the chemotherapy drug topotecan), were licensed from Tekmira to Talon Therapeutics, Inc. (formerly Hana Biosciences) in 2006. Talon is now responsible for all future development of these products, and Tekmira is entitled to receive milestone and royalty payments based on the successful development and commercialization of these three product candidates.
"We are pleased that Talon's Marqibo program received a positive recommendation from the Oncologic Drugs Advisory Committee, and we look forward to the FDA's completion of its review by May 13, 2012," said Dr. Mark J. Murray, Tekmira's President and CEO.
The ODAC provides the FDA with independent expert advice and recommendations; however the final decision regarding approval is made by the FDA.
About Marqibo
Marqibo is a novel, targeted Optisome(TM) encapsulated formulation product candidate of the FDA-approved anticancer drug vincristine. Talon has been developing Marqibo for the treatment of adult, Ph- ALL and adult aggressive NHL. Vincristine, a microtubule inhibitor, is FDA-approved for ALL and is widely used as a single agent and in combination regimens for treatment for hematologic malignancies such as lymphomas and leukemias. Marqibo is designed to provide prolonged circulation of the drug in the blood and accumulation at the tumor site. These characteristics are intended to increase the dose of vincristine delivered in a safe and effective manner. Talon's NDA seeking accelerated approval of Marqibo(R) (vincristine sulfate liposomes injection) has been accepted for filing by the FDA. Marqibo will be reviewed by the FDA under Subpart H -- Accelerated Approval of New Drugs for Serious or Life Threatening Illnesses, for the treatment of adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or that has progressed following two or more lines of anti-leukemia therapy. The PDUFA date is May 13, 2012.
About Talon Therapeutics
Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees. In addition to Marqibo, the Company has additional pipeline opportunities some of which, like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity. More information about Talon can be found at: www.talontx.com
About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.
The Tekmira Pharmaceuticals logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8319
Forward-Looking Statements and Information
Will TLON put out a PR about this great news?
Looking good TLON. It seems like we just might get the nod!
Why has the volume been so low? What is in store for this baby in the near future GETH?